IMIDIA participants are AstraZeneca, Boehringer Ingelheim, the French Atomic Energy Commission (CEA), Hannover Medical School (MHH), Imperial College London, Lilly, the National Centre for Scientific Research (CNRS), the National Institute of Health and Medical Research (INSERM), Novartis, Novo Nordisk, Roche, sanofi-aventis, Sarl Endocells, Servier, SIB Swiss Institute of Bioinformatics, Vrije University of Brussels, Dresden University of Technology, University of Geneva, University of Lausanne, University Paris Diderot, University of Pisa.
The close collaboration of academic teams, pharmaceutical companies and biotechs is providing unique levels of expertise and is forming a strong basis to reach the IMIDIA project goals.
For further details - please visit: http://www.imidia.org
The Innovative Medicines Initiative is a unique Public Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union represented by the European Commission.
IMI's overall goal is to make Europe again the world leader in
pharmaceutical research for the benefit of the economy and society, by
removing research bottlenecks in
|SOURCE Sanofi-aventis R&D|
Copyright©2010 PR Newswire.
All rights reserved